"The quarter's performance was impacted by the COVID-19 pandemic and related lockdowns, affecting our key businesses in India and US. We continue to focus on business continuity while ensuring employee safety," Lupin MD Nilesh Gupta said.
"Despite the challenges impacting revenues, we improved margins driven by tight expense control. We expect to continue the momentum on margin improvement. This is a pivotal year for us to deliver on our key complex generic assets and to sustain the momentum on the compliance front," he added.
Lupin's North America sales for Q1 FY2021 were at Rs 1,216 crore as compared to Rs 1,541.2 crore in the same quarter a year earlier, accounting for 35 per cent of its global sales,the company filing said.
The company's India formulation sales for Q1 FY2021 were at Rs 1,285.4 crore as against Rs 1,307.7 crore in the same quarter of FY2020, accounting for 37 per cent of its global sales,the company said.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)